Index -
P/E 9.45
EPS (ttm) 0.20
Insider Own 1.84%
Shs Outstand 67.31M
Perf Week -56.75%
Market Cap 128.78M
Forward P/E -
EPS next Y -0.54
Insider Trans -5.69%
Shs Float 66.88M
Perf Month -12.09%
Income 16.53M
PEG -
EPS next Q -0.11
Inst Own 49.61%
Short Float 5.38%
Perf Quarter 23.53%
Sales 119.18M
P/S 1.08
EPS this Y -3356.86%
Inst Trans -17.91%
Short Ratio 0.57
Perf Half Y 57.50%
Book/sh -0.46
P/B -
EPS next Y -55.21%
ROA 7.89%
Short Interest 3.60M
Perf Year 6.78%
Cash/sh 2.21
P/C 0.86
EPS next 5Y -0.90%
ROE -
52W Range 1.04 - 5.85
Perf YTD 21.94%
Dividend Est. -
P/FCF -
EPS past 5Y 67.21%
ROI -
52W High -67.69%
Beta 1.17
Dividend TTM -
Quick Ratio 1.16
Sales past 5Y 28.25%
Gross Margin 96.72%
52W Low 81.73%
ATR (14) 0.54
Dividend Ex-Date -
Current Ratio 1.16
EPS Y/Y TTM 122.25%
Oper. Margin 15.77%
RSI (14) 42.30
Volatility 15.76% 14.37%
Employees 122
Debt/Eq -
Sales Y/Y TTM 51.43%
Profit Margin 13.87%
Recom 2.29
Target Price 5.02
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 433.80%
Payout -
Rel Volume 0.96
Prev Close 1.98
Sales Surprise 114.28%
EPS Surprise 266.50%
Sales Q/Q 76.45%
Earnings May 08 AMC
Avg Volume 6.26M
Price 1.89
SMA20 -26.04%
SMA50 -20.16%
SMA200 12.49%
Trades
Volume 6,003,219
Change -4.55%
Date
Action
Analyst
Rating Change
Price Target Change
May-09-24 Upgrade
Wedbush
Neutral → Outperform
$8
May-06-24 Upgrade
Jefferies
Hold → Buy
$2.50 → $8
Apr-22-24 Upgrade
JP Morgan
Underweight → Neutral
Nov-14-22 Downgrade
BMO Capital Markets
Outperform → Market Perform
$3 → $2.60
Jul-07-22 Downgrade
Wedbush
Outperform → Neutral
$6 → $2
Jul-07-22 Downgrade
Piper Sandler
Overweight → Neutral
$10 → $1.50
Jul-07-22 Downgrade
Mizuho
Buy → Neutral
$16 → $4
Jul-07-22 Downgrade
Jefferies
Buy → Hold
$12 → $2
Jun-24-22 Initiated
BMO Capital Markets
Outperform
$9
Jan-18-22 Upgrade
Barclays
Underweight → Overweight
$7
Nov-15-21 Initiated
BTIG Research
Buy
$16
May-28-21 Downgrade
Barclays
Equal Weight → Underweight
$9 → $7
Mar-29-21 Initiated
JP Morgan
Overweight
$14
Mar-23-21 Upgrade
Jefferies
Hold → Buy
Sep-22-20 Downgrade
Guggenheim
Buy → Neutral
Jun-01-20 Downgrade
Jefferies
Buy → Hold
$16 → $10
May-14-20 Reiterated
H.C. Wainwright
Buy
$16 → $12
Mar-24-20 Upgrade
Wedbush
Neutral → Outperform
Mar-04-20 Initiated
Barclays
Equal Weight
$7
Nov-20-19 Initiated
Guggenheim
Buy
Show Previous Ratings
May-09-24 04:17PM
11:56AM
11:32AM
08:12AM
(Thomson Reuters StreetEvents)
07:48AM
07:29AM
Loading…
07:29AM
04:01AM
May-08-24 09:58PM
04:30PM
(Associated Press Finance)
04:10PM
04:10PM
May-07-24 04:15PM
May-06-24 07:09AM
May-02-24 08:08AM
07:37AM
12:11PM
Loading…
May-01-24 12:11PM
11:43AM
08:00AM
Apr-08-24 08:00AM
Apr-03-24 08:00AM
Mar-21-24 08:00AM
Mar-18-24 08:00AM
Mar-12-24 09:12AM
08:30AM
06:46AM
(Thomson Reuters StreetEvents)
Mar-11-24 05:34PM
05:20PM
04:10PM
Mar-04-24 08:00AM
Feb-27-24 11:52AM
08:00AM
Loading…
08:00AM
Jan-24-24 08:00AM
Jan-12-24 08:00AM
Jan-04-24 08:00AM
Dec-21-23 08:00AM
Nov-13-23 12:00PM
Nov-08-23 10:15AM
Nov-07-23 05:05PM
(Associated Press Finance)
04:15PM
Nov-01-23 08:00AM
Oct-31-23 08:00AM
Oct-30-23 08:00AM
Oct-18-23 04:30PM
Sep-05-23 04:05PM
Aug-25-23 09:35AM
Aug-10-23 04:05PM
Aug-08-23 05:30PM
04:26PM
(Associated Press Finance)
04:15PM
Aug-01-23 08:00AM
Jul-20-23 09:00AM
Jul-17-23 08:00AM
Jun-30-23 08:00AM
Jun-08-23 09:02AM
Jun-01-23 04:05PM
May-11-23 06:05AM
May-10-23 08:13AM
(Thomson Reuters StreetEvents) +5.81%
May-09-23 05:35PM
04:26PM
04:15PM
May-05-23 06:34AM
May-01-23 04:01PM
10:01AM
Apr-27-23 10:03AM
Apr-25-23 04:05PM
Mar-30-23 11:26AM
Mar-29-23 06:06AM
Mar-28-23 01:35PM
Mar-27-23 05:35PM
04:15PM
Mar-22-23 07:23PM
Mar-20-23 06:14AM
Feb-28-23 04:05PM
Feb-07-23 06:07AM
Jan-26-23 07:00AM
Jan-17-23 04:05PM
Jan-12-23 05:30AM
Jan-06-23 06:44PM
01:46PM
10:30AM
Jan-05-23 05:11PM
04:19PM
04:05PM
04:05PM
Dec-22-22 05:00PM
07:54AM
Dec-20-22 05:00PM
Dec-07-22 04:30PM
Nov-23-22 12:18PM
Nov-18-22 01:18PM
Nov-17-22 11:14AM
11:09AM
(American City Business Journals)
07:00AM
07:00AM
Nov-08-22 05:35PM
04:10PM
Nov-07-22 04:15PM
Nov-02-22 04:15PM
Nov-01-22 08:00AM
Oct-27-22 05:15PM
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McCarthy Sean A. CEO Mar 26 '24 Option Exercise 1.57 109,768 172,874 634,249 Mar 28 07:12 PM McCarthy Sean A. CEO Mar 19 '24 Sale 2.09 20,223 42,175 524,481 Mar 21 04:40 PM BELVIN MARCIA SVP, Chief Scientific Officer Mar 19 '24 Sale 2.09 12,795 26,684 168,579 Mar 21 04:37 PM Landau Jeffrey B Chief Business Officer Mar 19 '24 Sale 2.09 6,562 13,685 110,060 Mar 21 04:36 PM ROWLAND LLOYD A General Counsel Mar 19 '24 Sale 2.09 5,268 10,986 117,728 Mar 21 04:41 PM Ogden Christopher SVP, Finance and Accounting Mar 19 '24 Sale 2.09 2,971 6,196 85,686 Mar 21 04:38 PM McCarthy Sean A. CEO Dec 20 '23 Sale 1.38 13,551 18,710 454,704 Dec 22 04:16 PM ROWLAND LLOYD A General Counsel Dec 20 '23 Sale 1.38 4,077 5,629 97,996 Dec 22 04:11 PM BELVIN MARCIA SVP, Chief Scientific Officer Dec 20 '23 Sale 1.38 4,077 5,628 155,124 Dec 22 04:14 PM Landau Jeffrey B Chief Business Officer Dec 20 '23 Sale 1.38 4,077 5,628 86,622 Dec 22 04:12 PM Ogden Christopher SVP, Finance and Accounting Dec 20 '23 Sale 1.38 1,990 2,747 48,657 Dec 22 04:10 PM Ogden Christopher SVP, Finance and Accounting Dec 17 '23 Option Exercise 0.00 6,875 0 50,647 Dec 19 07:58 PM McCarthy Sean A. CEO Dec 17 '23 Option Exercise 0.00 37,500 0 468,255 Dec 19 07:57 PM Landau Jeffrey B Chief Business Officer Dec 17 '23 Option Exercise 0.00 11,250 0 90,699 Dec 19 07:56 PM ROWLAND LLOYD A General Counsel Dec 17 '23 Option Exercise 0.00 11,250 0 102,073 Dec 19 07:55 PM BELVIN MARCIA SVP, Chief Scientific Officer Dec 17 '23 Option Exercise 0.00 11,250 0 159,201 Dec 19 07:54 PM McCarthy Sean A. CEO Sep 22 '23 Sale 1.30 14,601 18,987 430,755 Sep 22 07:13 PM ROWLAND LLOYD A General Counsel Sep 22 '23 Sale 1.30 5,486 7,135 80,609 Sep 22 07:12 PM BELVIN MARCIA SVP, Chief Scientific Officer Sep 22 '23 Sale 1.30 4,119 5,356 147,951 Sep 22 07:16 PM Landau Jeffrey B Chief Business Officer Sep 22 '23 Sale 1.30 4,119 5,356 76,379 Sep 22 07:15 PM McCarthy Sean A. CEO May 19 '23 Option Exercise 1.57 16,535 26,041 405,356 May 23 04:52 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite